Testing KSI-101 eye injections for swelling from inflammation
Part of Eyes & vision clinical trials.
This trial tests a new injected medicine (KSI-101) for people with swelling in the back of the eye caused by inflammation. The medicine is given directly into the eye to see if it can reduce the swelling and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have swelling in the center of your retina (macular edema) that is caused by inflammation (not from diabetes, a blocked vein, or age-related macular degeneration).
- That swelling measures at least 400 microns (about the width of a hair) on a special scan called an OCT.
- Fluid is present inside or under your retina on that scan.
- Your vision in the study eye is between 20/40 and 20/320 (you can read some lines on an eye chart but not a newspaper).
- You have a history of or active inflammation inside your eye that is not caused by an infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called KSI-101 given as an injection into the eye to treat swelling in the center of the retina caused by inflammation. It may help people whose vision has gotten worse due to this type of swelling.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a new medicine, BI 1815368, to see if it can help people with diabetic macular edema, a condition that causes swelling in the back of the eye and can blur vision. If you qualify, you may be able to try this treatment and help researchers learn if it works.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This trial tests an eye injection called KIO-104 to treat macular edema (swelling in the center of the retina) caused by conditions like uveitis, diabetes, or vein blockage. The goal is to see if it is safe and improves vision.
Hear when a new Macular Edema Secondary to Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.